Dr. Shreeniwas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
819 sutter ave
East Palo Alto, CA 94303Phone+1 650-714-4445
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Critical Care Medicine (Anesthesiology), 1994 - 1995- New York Presbyterian Hospital (Columbia Campus)Fellowship, Pulmonary Disease and Critical Care Medicine, 1992 - 1994
- New York Presbyterian Hospital (Columbia Campus)Fellowship, Cardiovascular Disease, 1989 - 1991
UMass Chan Medical SchoolResidency, Internal Medicine, 1986 - 1988
ArMed Forces Medical College PuneClass of 1982
Certifications & Licensure
CA State Medical License 1997 - 2026
NY State Medical License 1989 - 1998
NJ State Medical License 1990 - 1997- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 75 citationsMacrovascular and microvascular endothelium during long-term hypoxia: Alterations in cell growth, monolayer permeability, and cell surface coagulant propertiesRevati Shreeniwas, Satoshi Ogawa, F. Cozzolino, G. Torcia, N. Braunstein
Journal of Cellular Physiology. 1991-01-01 - 285 citationsHypoxic induction of interleukin-8 gene expression in human endothelial cells.M. Karakurum, Revati Shreeniwas, Jing Xian Chen, David J. Pinsky, Shirley ShiDu Yan
The Journal of Clinical Investigation. 1994-04-01 - 33 citationsModulation of endothelial function by hypoxia: perturbation of barrier and anticoagulant function, and induction of a novel factor X activator.Satoshi Ogawa, Revati Shreeniwas, Caesar C. Butura, Jerold Brett, David M. Stern
Advances in Experimental Medicine and Biology. 1990-01-01
Press Mentions
Bright Minds Begins Subject Dosing in Phase I Dravet Syndrome TrialSeptember 1st, 2022- Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical OfficerJuly 26th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
